Evidence map›Paper›PMID 36528617›Full record

ArticleCellular & molecular biology letters2022

PSMC3 promotes RNAi by maintaining AGO2 stability through USP14.

Yan Jia, Jianing Zhao, Tao Yu, Xue Zhang, Xiaozhen Qi, Tongxin Hao, Zeyuan Jin, Xiaoqing Zhao

Open access · goldAbstract read
In one paragraph

Article in Cellular & molecular biology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yan Jia *Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China. jiayan@tmu.edu.cn.ORCID http://orcid.org/0000-0002-7631-225X
Jianing Zhao *Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Tao Yu *Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Xue ZhangDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Xiaozhen QiDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Tongxin HaoDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Zeyuan JinDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qi-Xiang- Tai Road, Tianjin, 300070, China.
Xiaoqing ZhaoDepartment of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, China. 862046719@qq.com.
Tianjin Medical University · CNSecond Hospital of Shandong University · CN

Funding

Natural Science Foundation of Tianjin City 08JCZDJC23300Natural Science Foundation of Tianjin City 09JCZDJC17500
6 · The paper itself

Abstract

backgroundArgonaute 2 (AGO2), the only protein with catalytic activity in the human Argonaute family, is considered as a key component of RNA interference (RNAi) pathway. Here we performed a yeast two-hybrid screen using the human Argonaute 2 PIWI domain as bait to screen for new AGO2-interacting proteins and explored the specific mechanism through a series of molecular biology and biochemistry experiments.

methodsThe yeast two-hybrid system was used to screen for AGO2-interacting proteins. Co-immunoprecipitation and immunofluorescence assays were used to further determine interactions and co-localization. Truncated plasmids were constructed to clarify the interaction domain. EGFP fluorescence assay was performed to determine the effect of PSMC3 on RNAi. Regulation of AGO2 protein expression and ubiquitination by PSMC3 and USP14 was examined by western blotting. RT-qPCR assays were applied to assess the level of AGO2 mRNA. Rescue assays were also performed.

resultsWe identified PSMC3 (proteasome 26S subunit, ATPase, 3) as a novel AGO2 binding partner. Biochemical and bioinformatic analysis demonstrates that this interaction is performed in an RNA-independent manner and the N-terminal coiled-coil motif of PSMC3 is required. Depletion of PSMC3 impairs the activity of the targeted cleavage mediated by small RNAs. Further studies showed that depletion of PSMC3 decreased AGO2 protein amount, whereas PSMC3 overexpression increased the expression of AGO2 at a post-translational level. Cycloheximide treatment indicated that PSMC3 depletion resulted in a decrease in cytoplasmic AGO2 amount due to an increase in AGO2 protein turnover. The absence of PSMC3 promoted ubiquitination of AGO2, resulting in its degradation by the 26S proteasome. Mechanistically, PSMC3 assists in the interaction of AGO2 with the deubiquitylase USP14(ubiquitin specific peptidase 14) and facilitates USP14-mediated deubiquitination of AGO2. As a result, AGO2 is stabilized, which then promotes RNAi.

conclusionOur findings demonstrate that PSMC3 plays an essential role in regulating the stability of AGO2 and thus in maintaining effective RNAi.

Indexed as

Proteasome Endopeptidase ComplexRNA InterferenceArgonaute ProteinsATPases Associated with Diverse Cellular ActivitiesHumansImmunoprecipitationProteolysisUbiquitinationUbiquitin ThiolesteraseAGO2 protein, humanArgonaute ProteinsATPases Associated with Diverse Cellular ActivitiesProteasome Endopeptidase ComplexPSMC3 protein, humanUbiquitin ThiolesteraseUSP14 protein, humanAGO2deubiquitinationproteasomePSMC3RNAiUSP14

Identifiers

PMID36528617
PMCPMC9759854
OpenAlexW4311978579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.